Juvenescence lands $50 mln Series A
Juvenescence, a developer of therapies for ageing and age-related diseases, has raised $50 million in Series A funding. The investors in this round were not named.
12 June 2018•1 min read
Juvenescence, a developer of therapies for ageing and age-related diseases, has raised $50 million in Series A funding. The investors in this round were not named.
